ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Vitamin D supplements, sleep could help manage pain

Bacopa: The Herb That May Increase Your Brain Power

Lilac Oil: More Than Just for Fragrance

Eat More Yogurt and Avoid Osteoporosis

Safflower: An Economically Important Herb That Can Benefit Humans and Animals Alike

What Is Bilberry Good For?

Coffee, herbal tea may help prevent liver fibrosis

Crafty Uses for Carrot Seed Oil

Resveratrol Improves Arteries

New research adds evidence to association between omega 3 levels and brain maintenance

 
Print Page
Email Article

New Treatment Method for Alzheimer's Disease

  [ Not Yet Rated ]   [ Discuss This Article ]
By Press Rlease • www.ProHealth.com • March 2, 2000


IRVINE, Calif., Feb. 23 /PRNewswire/ -- NeoTherapeutics, Inc. announced today that the Company has been issued a new U.S. patent covering a method for controlling the expression of genes to produce neurotrophic growth factors to stimulate nerve cell growth within the human body. This patent further secures NeoTherapeutics' proprietary position in nerve regeneration.

"This is one of many exciting new advances in the dynamic medical field of nerve regeneration," commented Dr. Michelle Glasky, Vice President, Scientific Affairs of NeoTherapeutics. "This patent covers one of the actions of NEOTROFIN(TM), that of causing nerve sprouting, which our research studies suggest may lead to the formation of new nerve connections. We believe that this effect is of vital importance to the functional regeneration of the nervous system."

U.S. Patent No. 6,027,936 describes how certain purine derivatives, a class of drug compounds which includes NeoTherapeutics' lead compound NEOTROFIN(TM) (AIT-082, leteprinim potassium), stimulate neuritogenesis, or the sprouting of nerve cells, by selectively and controllably inducing the in vivo genetic expression of at least one naturally occurring genetically- encoded molecule. NEOTROFIN(TM) induces the production of several different types of "nerve growth" factors in the central nervous system and it is these factors which are important for the growth, maturation and sprouting of nerve cells. Recent research has indicated that the ability to induce nerve growth factors may be important in treating neurodegenerative diseases including Alzheimer's disease.

Previously, the United States Patent and Trademark Office granted NeoTherapeutics three patents covering the Company's technology platform, which includes NeoTherapeutics' lead drug candidate, NEOTROFIN(TM). NeoTherapeutics has seven additional patent applications pending in the U.S. as well as patent applications in development for additional technologies. NeoTherapeutics has also filed, and in some cases received, international patent applications corresponding to its U.S. patents to further expand its technology base.

NEOTROFIN(TM) is being developed for nerve repair and regeneration, with Alzheimer's disease as its first clinical indication. Pre-clinical studies have demonstrated that NEOTROFIN(TM) causes the production of multiple natural nerve growth (neurotrophic) factors and restores function in animal models of cognitive decline, aging, neurodegeneration, and spinal cord injury. Human clinical studies have shown NEOTROFIN(TM) to be safe and tolerable and demonstrated its positive effects on memory and behavioral function in patients with Alzheimer's disease.

According to figures from the Alzheimer's Association, Alzheimer's disease presently affects over 4 million people in the U.S. and approximately 12 million patients worldwide, with associated health care costs of $80-$100 billion per year. Currently marketed drugs, such as Pfizer's Aricept(R) and the soon to be marketed Exelon(R) (Novartis), have been approved to slow the progression of symptoms of Alzheimer's disease.

NeoTherapeutics research program is focused on designing and developing small molecules capable of treating a range of neurological diseases and conditions such as Alzheimer's and Parkinson's diseases, stroke, and spinal cord injury.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Safely Burn Away Body Fat Safely Burn Away Body Fat
Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map